DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Proposed Information Collection Activity; Comment Request

Proposed Projects:

Title: Runaway and Homeless Youth Management Information System (RHYMIS).

OMB No. 0970–0123.

Description: In the Runaway and Homeless Youth Act (42 U.S.C. 5701 *et seq.*) Congress mandated that the Department of Health and Human Services (HHS) report regularly on the status of HHS-funded programs serving runaway and homeless youth in Basic Center programs (BC), Transitional Living programs (TLP) and Street Outreach programs. Organizations funded under the Runaway and Homeless Youth program are required by statute (42 U.S.C. 5712, 42 U.S.C. 5714–2) to meet several data collection and reporting requirements, including maintaining client statistical records and submitting annual program reports regarding the profile of the youth and families served and the services provided to them. The RHYMIS data supports these organizations as they carry out a variety of integrated, ongoing responsibilities and projects, including legislative reporting requirements, planning and public policy development for runaway and homeless youth programs, accountability monitoring, program management, research, and evaluation. RHYMIS has been redesigned and streamlined to reduce the collection burden upon respondents and to capture key information previously not requested.

Respondents: Not-for-profit institutions.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
BC/TLP Youth Profile	400	185	.75	55,500
Street Outreach Report	140	2	.40	112
BC/TLP Brief Contacts	400	100	.10	4,000
BC/TLP Turnaways	400	50	.10	2,000
Date Transfer	400	2	.50	400
Estimated Total Annual Burden Hours				62,012

In compliance with the requirements of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: December 21, 2000.

Bob Sargis,

Reports Clearance Officer.

[FR Doc. 00–33038 Filed 12–27–00; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

HRSA AIDS Advisory Committee; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92–463), announcement is made of the following National Advisory body scheduled to meet during the month of February 2001.

Name: HRSA AIDS Advisory Committee (HAAC).

Date and Time: February 8, 2001; 8:30 a.m.—5:00 p.m., February 9, 2001; 8:30 a.m.—1:30 p.m.

Place: Four Points Sheraton Bethesda, 8400 Wisconsin Avenue, Bethesda, Maryland 20814, Telephone: (301) 941–2704.

The meeting is open to the public.

Agenda: Agenda items for the meeting include reauthorization implementation update of the Ryan White CARE Act, program updates, and discussion of HIV prevention and care linkages.

Anyone requiring further information should contact Joan Holloway, HIV/AIDS Bureau, Parklawn Building, Room 7–13, 5600 Fishers Lane, Rockville, Maryland 20857, telephone (301) 443–5761.

Dated: December 21, 2000.

Jane Harrison,

Director, Division of Policy Review and Coordination.

[FR Doc. 00–33088 Filed 12–27–00; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment Request; Case-Control Study of Cancer and Related Disorders Among Benzene-Exposed Workers in China

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Proposed Collection: Title: Case-Control Study of Cancer and Related Disorders Among Benzene-Exposed Workers in China. Type of Information Collection Request: Extension. (OMB No. 0925–0454 expires 3/31/01) Need

and Use of Information Collection: A case-control study will examine the relationship between exposure to benezene and the risk of lymphohematopoietic malignancies and related disorders and lung cancer in Chinese workers. Cases and controls will be selected from participants in a recent cohort study of benzene-exposed workers in China. The data will be used by the NCI to examine risk among workers exposed to low levels of benzene, and to characterize the dose and time-specific relationship between benzene exposure and disease risk. Frequency of Response: One-time study. Affected Public: Individuals or households. Type of Respondents: Workers. The annual reporting burden is as follows: Estimated Number of Respondents: 1,545; Estimated Number of Responses per Respondent: One; Average Burden Hours per Response: 0.75; and Estimated Total Annual Burden Hours Requested: 386.

There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

Request for Comments: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection or information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Richard Hayes, Project Officer, National Cancer Institute, Executive Plaza South, Room 8114, Rockville, Maryland 20892–7364, or call non-toll-free number (301) 496–9093, or FAX your request to (301) 402–1819, or E-mail your request, including your address, to *HayesR@exchange.nih.gov.*

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received on or before February 26, 2001.

Dated: December 18, 2000.

Reesa L. Nichols,

NCI Project Clearance Liaison.

[FR Doc. 00–33085 Filed 12–27–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Transgenic Zebrafish with Vascular Specific Expression of Exogenous Genes Driven by the Zebrafish Fli-1 Promoter

Brant M. Weinstein, Nathan N. Lawson (NICHD)

DHHS Reference No. E–003–01/0

Licensing Contact: Marlene Shinn; 301/496–7056 ext. 285; email: shinnm@od.nih.gov

The technology portrayed in this invention is available through a Biological Materials License for research tools and diagnostic tests. Zebrafish are an important and valuable model system for high-throughput mutational or pharmacological screens for genes or molecules with important roles in blood vessel growth or differentiation. This invention consists of germline transgenic zebrafish lines in which the expression of green fluorescent protein (EGFP) is driven by zebrafish Fli-1 promoter sequences. These transgenic lines display bright, uniform, and persistent expression of EGFP protein throughout the vascular system. The Fli promoter also drives transient EGFP expression in cranial neural crest and its derivatives. The transgenics allow straightforward, noninvasive fluorescent visualization of virtually all blood vessels in the animal throughout embryonic and early larval development.

These Fli-EGFP transgenics have a number of potential applications. They can be used to help identify endogenous genes important for blood vessel formation, either by screening mutagenized transgenic embryos for vascular specific mutants or by preparing vascular specific cDNA libraries for use in novel gene discovery. They also provide an efficient method for performing high-throughput in vivo screening for antiangiogenic or proangiogenic drugs and other compounds. Using transgenic zebrafish for these screens has the added benefit of simultaneously revealing toxic and teratogenic effects of the tested agents on a whole, developing organism.

Transcranial Magnetic Stimulation Coil for Specific Non-Invasive Deep Brain Stimulation

Abraham Zangen (NIDA), Roy Wise (NIDA), Mark Hallett (NINDS), Yiftach Roth (EM), Pedro Miranda (NINDS)

DHHS Reference No. E–223–00/0 filed 20 Oct 2000

Licensing Contact: Dale Berkley; 301/496–7735 ext. 223; e-mail: berkleyd@od.nih.gov

The invention is a magnetic stimulator that is placed in contact with the head of a subject to magnetically stimulate the brain. The invention has applications in the treatment of neurophysiological or cardiovascular conditions, and may be of particular utility in the treatment of disorders associated with deep regions of the brain, such as drug addiction and depression. The unique coil shape of the stimulator is designed to target deep brain regions like the nucleus accumbens, which are associated with the biological mechanism underlying drug abuse. Deep regions of the brain are also implicated in depressive disorders, and this coil is likely to offer an improvement in the transcranial magnetic stimulation therapy currently being tested for treatment of depression.

Peroxynitrite Generators, Compositions Comprising Same, and Methods for Treating Biological Disorders Using Same

Challice L. Bonifant, Joseph E. Saavedra and Larry K. Keefer (NCI)

DHHS Reference No. E–175–00/0 filed 02 June 2000